Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00235914 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Parkinsonism Relat Disord
December 2024
Roche Pharma Research and Early Development (pRED), Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Introduction: Prasinezumab was shown to potentially delay motor progression in individuals with early-stage Parkinson's disease (PD) who were either treatment-naïve or on monoamine oxidase type B inhibitor (MAO-Bi) therapy in the PASADENA study. We report the rationale, design, and baseline patient characteristics of the PADOVA study, designed to evaluate prasinezumab in an early-stage PD population receiving standard-of-care (SOC) symptomatic medications.
Methods: PADOVA (NCT04777331) is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, in which individuals with early-stage PD on SOC stable symptomatic monotherapy (levodopa or MAO-Bi) receive intravenous prasinezumab 1500 mg every 4 weeks.
The effect of L-dopa and DBS on cortical oscillations in Parkinson's disease analyzed by hidden Markov model algorithm.
Neuroimage
January 2025
Department of Neurosurgery, Affiliated Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Article Synopsis
- Parkinson's disease (PD) is a movement disorder linked to the degeneration of dopamine-producing neurons, and treatments like Levodopa (L-dopa) and Subthalamic Deep Brain Stimulation (STN-DBS) have distinct effects on brain activity that need further study.
- In a study involving 21 PD patients on L-dopa and 11 patients with STN-DBS, researchers used Magnetoencephalogram (MEG) data to analyze how these treatments impacted brain state dynamics through a statistical method called the Time-delay embedded Hidden Markov Model (TDE-HMM).
- Results showed that L-dopa enhanced motor state and beta wave activity in the brain, correlating
Dopaminergic Treatment and Episodic Memory in Parkinson's Disease: A Meta-analysis of the Literature.
Neuropsychol Rev
December 2024
Laboratory of Neuropsychology of Memory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Via Ardeatina 306, 00179, Rome, Italy.
To date, few studies have focused on the benefits of dopaminergic treatment on episodic memory functions in patients affected by Parkinson's disease (PD). We conducted a meta-analysis to determine the effects of pharmacological therapy with dopamine in alleviating episodic memory deficits in Parkinson's patients. A secondary aim was to evaluate the role of dopamine in episodic memory circuits and thus in different memory systems.
View Article and Find Full Text PDFSustained effects of repeated levodopa (L-DOPA) administration on reward circuitry, effort-based motivation, and anhedonia in depressed patients with higher inflammation.
Brain Behav Immun
December 2024
Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, USA; The Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322. Electronic address:
Inflammatory biomarkers like C-reactive protein (CRP) are elevated in a subset of patients with depression and have been associated with lower functional connectivity (FC) in a ventral striatum (VS) to ventromedial prefrontal cortex (vmPFC) reward circuit and symptoms of anhedonia. Evidence linking these relationships to the effects of inflammation on dopamine is consistent with our recent findings that acute levodopa (L-DOPA) increased VS-vmPFC FC in association with deceased anhedonia in depressed patients with higher but not lower CRP (>2 versus ≤ 2 mg/L). To determine whether repeated L-DOPA administration caused sustained effects on FC and behavior in these patients, medically stable depressed outpatients with CRP > 2 mg/L and anhedonia (n = 18) received one week of three doses of L-DOPA (150-450 mg/day/week with carbidopa) or placebo in a randomized order.
View Article and Find Full Text PDFLevodopa is associated with reduced development of new-onset geographic atrophy in patients with age-related macular degeneration.
Eye Vis (Lond)
November 2024
Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Article Synopsis
- Geographic atrophy (GA) is a major cause of vision loss in patients with age-related macular degeneration (AMD), and existing treatments have limitations and risks.
- Researchers conducted a study using data from the Vestrum Health Retina Database to assess whether levodopa (L-DOPA) could lower the risk of developing new-onset GA in patients with non-neovascular AMD.
- The findings indicated that L-DOPA use was associated with a significantly lower likelihood of new-onset GA, suggesting it may be a beneficial factor in managing this condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!